To: N. Reed Dunnick, DM
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Academic RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Combined quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for prognosis in high-grade gastroenteropancreatic neuroendocrine neoplasms.Acad Radiol. 2021; S1076633221004621
- Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients.J Nucl Med. 2019; 60: 377-385
- Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.Eur J Nucl Med Mol Imaging. 2018; 45: 262-277
- Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance.Theranostics. 2017; 7: 1149-1158
Article Info
Publication History
Published online: February 23, 2022
Accepted:
January 15,
2022
Received:
January 11,
2022
Identification
Copyright
© 2022 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.
